Hormonal contraceptive use and risk of HIV-1 disease progression

AIDS

Volumn 27, Issue 2, 2013, Pages 261-267

  Heffron, Renee ^a   Mugo, Nelly ^a,b,c   Ngure, Kenneth ^a,b,d   Celum, Connie ^a   Donnell, Deborah ^a,e   Were, Edwin ^f   Rees, Helen ^g   Kiarie, James ^a,b,c   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KENYATTA NATIONAL HOSPITAL   (Kenya)

^c UNIVERSITY OF NAIROBI   (Kenya)

^d JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MOI UNIVERSITY   (Kenya)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

antiretroviral therapy; CD4 cell count; death; HIV 1; hormonal contraception; women

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

ADULT; AFRICA; ARTICLE; DISEASE COURSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AFRICA, EASTERN; AFRICA, SOUTHERN; CD4 LYMPHOCYTE COUNT; CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84872395405     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ad473     Document Type: Article

References (26)

1. Trunova N, Tsai L, Tung S, Schneider E, Harouse J, Gettie A, et al. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 2006; 352:169-177.
2. Sagar M, Lavreys L, Baeten JM, Richardson BA, Mandaliya K, Ndinya-Achola JO, et al. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 2004; 18:615-619.
3. Lavreys L, Baeten JM, Kreiss JK, Richardson BA, Chohan BH, Hassan W, et al. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J Infect Dis 2004; 189:303-311.
4. Stringer EM, Levy J, Sinkala M, Chi BH, Matongo I, Chintu N, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009; 23:1377-1382.
5. Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007; 21:749-753.
6. Stringer EM, Giganti M, Carter R, El-Sadr W, Abrams E, Stringer JS. Hormonal contraception and disease progression: a multi-country cohort analysis of the MTCT-Plus Initiative. AIDS 2009; 23:S69-S77.
7. Polis CB, Wawer MJ, Kiwanuka N, Laeyendecker O, Kagaayi J, Lutalo T, et al. Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda. AIDS 2010; 24:1937-1944.
8. Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, Ma YR, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2011; 57:157-164.
9. World Health Organization. Department of Reproductive Health and Research. Hormonal contraception and HIV: Technical statement. Geneva, Switzerland: World Health Organization 2012; 2012.
10. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
11. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-833.
12. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, Baeten J, et al. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS ONE 2009; 4:e5272.
13. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, Smith J. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect 2004; 10:530-536.
14. Ngure K, Heffron R, Mugo NR, Celum C, Cohen CR, Odoyo J, et al. Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS 2012; 26:513-518.
15. Efron B. Efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 1977; 72:557-565.
16. Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, et al. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003; 33:585-593.
17. Pardthaisong T, Gray RH, McDaniel EB. Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand. Lancet 1980; 1:509-512.
18. Bracken MB, Hellenbrand KG, Holford TR. Conception delay after oral contraceptive use: the effect of estrogen dose. Fertil Steril 1990; 53:21-27.
19. Mishell DR Jr. Pharmacokinetics of depot medroxyprogester-one acetate contraception. J Reprod Med 1996; 41:381-390.
20. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79-97.
21. Lieve VP, Shafer LA, Mayanja BN, Whitworth JA, Grosskurth H. Effect of pregnancy on HIV disease progression and survival among women in rural Uganda. Trop Med Int Health 2007; 12:920-928.
22. Mayanja BN, Shafer LA, Van der Paal L, Kyakuwa N, Ndembi N, Hughes P, et al. Effect of pregnancy on immunological and virological outcomes of women on ART: a prospective cohort study in rural Uganda, 2004-2009. Trop Med Int Health 2012; 17:343-352.
23. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
24. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
25. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, Chillag K, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Oral abstract WELBC01. International AIDS Society 2011; Rome, Italy. 2011.
26. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.N Engl J Med 2012; 367:399-410.